FDA Brief

Warning letters Drugs

FDA warning letter to

GSC Products, LLC

High riskIssued May 18Posted May 26Center for Drug Evaluation and Research (CDER)

FDA told GSC Products its Sinus Plumber headache nasal spray is an unapproved new drug sold online without FDA approval.

What happened

FDA reviewed two websites, sinusplumber.com and greensations.com, in March 2026; the sinusplumber.com site also sends buyers to an Amazon storefront. FDA found the Sinus Plumber Headache Nasal Spray labeled to relieve tension, cluster, sinus and migraine headaches, pain, nausea and inflammation. Because it is sprayed inside the nose and contains ingredients not allowed for over-the-counter pain drugs, FDA says it is an unapproved new drug and misbranded.

What FDA found

  1. The product is a drug because its label says it treats headaches, migraines and other conditions.

    Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1); 21 CFR 201.128
  2. The product is a new drug with no FDA-approved application, so it cannot be shipped interstate.

    Sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d)
  3. The over-the-counter pain drug rule it relies on covers only oral products, not a spray used inside the nose.

    OTC monograph M013.1
  4. Its claims about sinuses, tension and cluster headaches, nausea, inflammation and circulation go beyond what the over-the-counter pain drug rule allows.

    OTC monograph M013.50(b)
  5. Feverfew, arnica montana, oleoresin capsicum, caffeine anhydrous and peppermint oil are not permitted as single active ingredients or in this combination.

    OTC monograph M013.10 and M013.20
  6. The product is misbranded because it is a nonprescription drug that does not meet the requirements for marketing without an approved application.

    Section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee)

What FDA wants

FDA asks the company to reply in writing within 15 business days to FDAAdvisory@fda.hhs.gov with the steps taken to fix each violation, how it will prevent recurrence, and supporting documents, using reference number 729653 in the subject line. If the company believes it is not in violation, it should send that information for FDA to consider.

Who should pay attention

  • online sellers and Amazon storefront operators of over-the-counter remedies
  • makers of capsaicin or botanical nasal sprays
  • brands relying on over-the-counter pain drug monograph claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk